🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Caspofungin for Pneumocystis Pneumonia in PLWHIV.

Recruitingn/aAges 18 Years - 60 YearsAllInstituto Nacional de Enfermedades Respiratorias
NCT06691321 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Pneumocystis jirovecii pneumonia is a significant concern in peaple with HIV/AIDS, often severe and potentially fatal. While trimethoprim/sulfamethoxazole remains the primary treatment, safety concerns exist with alternative options. Research on Pneumocystis jirovecii's beta-D glucan composition has prompted investigations into echinocandins like caspofungin, showing promise in murine models and some positive results in human studies. Evaluating caspofungin's efficacy through observational studies is crucial due to safety advantages over current treatments and limited documented data.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosis of probable or proven PCP, according to its diagnostic classification (refer to classification at the end of this section). * Have clinical laboratory and virological diagnostic laboratory studies at the time of admission. * Classification criteria for Pneumonia by P. jirovecii according to Robert-Gangneux et al.: Proven: Confirmation by pathology or microbiology. Possible: Presence of three out of four clinical or radiological criteria. Probable: Presence of one clinical or radiological criterion without another identified microorganism. Exclusion Criteria: * With a treatment switch to caspofungin after day 7 of treatment initiation (applies only to group B). * Patients who have developed an additional opportunistic lung infection during their hospitalization, other than cytomegalovirus pneumonitis or SARS-CoV-2 pneumonia.
💊

What it tests

  • Not listed
📍

Where

1 site
Center for Research in Infectious Diseases (CIENI)
Mexico City, Mexico
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy